Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Möchten Sie über diese Zeitschrift informiert bleiben? Klicken Sie bitte auf die Buttons, um unsere Alerts zu abonnieren.
Treatment with Bifidobacterium longum 51A attenuates intestinal damage and inflammatory response in experimental colitis
in Beneficial MicrobesSearch for other papers by F.A. Abrantes in
Current site
Google Scholar
Search for other papers by B.B. Nascimento in
Current site
Google Scholar
Search for other papers by M.E.R. Andrade in
Current site
Google Scholar
Search for other papers by P.A.V. de Barros in
Current site
Google Scholar
Search for other papers by C.T. Cartelle in
Current site
Google Scholar
Search for other papers by F.S. Martins in
Current site
Google Scholar
Search for other papers by J.R. Nicoli in
Current site
Google Scholar
Search for other papers by R.M.E. Arantes in
Current site
Google Scholar
Search for other papers by S.V. Generoso in
Current site
Google Scholar
Search for other papers by S.O.A. Fernandes in
Current site
Google Scholar
Search for other papers by V.N. Cardoso in
Current site
Google Scholar
This study evaluated the effects of Bifidobacterium longum 51A on the intestinal mucosa and inflammatory response in experimental colitis. Colitis was induced by administration of 3.5% dextran sodium sulphate (DSS) solution for 7 days. Two periods of administration were performed: treatment (T) group, mice received Bifidobacterium only during disease induction (7 days); total treatment (TT) group, mice received Bifidobacterium for 10 days before and during disease induction. The probiotic effects on intestinal permeability, inflammatory infiltrate, histological analysis, cytokines, chemokines and sIgA were evaluated. Bifidobacterium administration in the T group showed reduction in intestinal permeability and lower IL-1β, myeloperoxidase, and eosinophil peroxidase levels compared to those in the colitis group (P<0.05). Bifidobacterium administration in the TT group attenuated severe lesions in the colon and reduced eosinophil peroxidase level (P<0.05). B. longum 51A treatment modality was more effective than total treatment and reduced the inflammatory response and its consequences on intestinal epithelium.
Kauf
Sofortzugang erwerben (PDF-Download und unbegrenzter Online-Zugang):
Institutszugang
Melden Sie sich mit Open Athens, Shibboleth oder Ihren institutionellen Anmeldedaten an.
Persönliche Anmeldung
Melden Sie sich mit Ihrem brill.com-Konto an
-
Andrade, M.E., Santos, R.D., Soares, A.D., Costa, K.A., Fernandes, S.O., De Souza, C.M., Cassali, G.D., De Souza, A.L., Faria, A.M. and Cardoso, V.N., 2016. Pretreatment and treatment with L-arginine attenuate weight loss and bacterial translocation in dextran sulfate sodium colitis. Journal of Parenteral and Enteral Nutrition 40: 1131-1139. https://doi.org/10.1177/0148607115581374
-
Andrade, M.E.R., Viera de Barros, P.A., Dos Reis Menta, P.L., Ferreira Costa, G.M., Mendes Miranda, S.E., Lacerda Leocádio, P.C., De Almeida-Leite, C.M., De Vasconcelos Generoso, S., Alvarez Leite, J.I. and Cardoso, V.N., 2019. Arginine supplementation reduces colonic injury, inflammation and oxidative stress of DSS-induced colitis in mice. Journal of Functional Foods 52: 360-369. https://doi.org/10.1016/j.jff.2018.11.019
-
Arantes, R.M.E. and Nogueira, A.M.M.F., 1997. Distribution of enteroglucagon- and peptide YY-immunoreactive cells in the intestinal mucosa of germ-free and conventional mice. Cell and Tissue Research 290: 61-69. https://doi.org/10.1007/s004410050908
-
Balaha, M., Kandeel, S. and Elwan, W., 2016. Garlic oil inhibits dextran sodium sulfate-induced ulcerative colitis in rats. Life Sciences 146: 40-51. https://doi.org/10.1016/j.lfs.2016.01.012
-
Cho, J.H., 2008. The genetics and immunopathogenesis of inflammatory bowel disease. Nature Reviews Immunology 8: 458-466. https://doi.org/10.1038/nri2340
-
Elian, S.D.A., Souza, E.L.S., Vieira, A.T., Teixeira, M.M., Arantes, R.M.E., Nicoli, J.R. and Martins, F.S., 2015. Bifidobacterium longum subsp. infantis BB-02 attenuates acute murine experimental model of inflammatory bowel disease. Beneficial Microbes 6: 277-286. https://doi.org/10.3920/bm2014.0070
-
Fanning, S., Hall, L.J., Cronin, M., Zomer, A., MacSharry, J., Goulding, D., O’Connell Motherway, M., Shanahan, F., Nally, K., Dougan, G. and van Sinderen, D., 2012. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proceedings of the National Academy of Sciences of the USA 109: 2108-2113. https://doi.org/10.1073/pnas.1115621109
-
Guerra, P.V., Lima, L.N., Souza, T.C., Mazochi, V., Penna, F.J., Silva, A.M., Nicoli, J.R. and Guimaraes, E.V., 2011. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World Journal of Gastroenterology 17: 3916-3921. https://doi.org/10.3748/wjg.v17.i34.3916
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E., 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology 11: 506. https://doi.org/10.1038/nrgastro.2014.66
-
Hooper, L.V., Littman, D.R. and Macpherson, A.J., 2012. Interactions between the microbiota and the immune system. Science 336: 1268-1273. https://doi.org/10.1126/science.1223490
-
Jadhav, S.R., Shandilya, U.K. and Kansal, V.K., 2013. Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice. Journal of Dairy Research 80: 21-27. https://doi.org/10.1017/S0022029912000684
-
Johansson, M.E.V., Gustafsson, J.K., Sjöberg, K.E., Petersson, J., Holm, L., Sjövall, H. and Hansson, G.C., 2010. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PloS One 5: e12238. https://doi.org/10.1371/journal.pone.0012238
-
Kanauchi, O., Andoh, A. and Mitsuyama, K., 2013. Effects of the modulation of microbiota on the gastrointestinal immune system and bowel function. Journal of Agricultural and Food Chemistry 61: 9977-9983. https://doi.org/10.1021/jf402441f
-
Koboziev, I., Reinoso Webb, C., Furr, K.L. and Grisham, M.B., 2014. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radical Biology and Medicine 68: 122-133. https://doi.org/10.1016/j.freeradbiomed.2013.11.008
-
Leonel, A.J., Teixeira, L.G., Oliveira, R.P., Santiago, A.F., Batista, N.V., Ferreira, T.R., Santos, R.C., Cardoso, V.N., Cara, D.C., Faria, A.M.C. and Alvarez-Leite, J., 2012. Antioxidative and immunomodulatory effects of tributyrin supplementation on experimental colitis. British Journal of Nutrition 109: 1396-1407. https://doi.org/10.1017/S000711451200342X
-
Liu, Y., Wang, X., Hou, Y., Yin, Y., Qiu, Y., Wu, G. and Hu, C.-A.A., 2017. Roles of amino acids in preventing and treating intestinal diseases: recent studies with pig models. Amino Acids 49: 1277-1291. https://doi.org/10.1007/s00726-017-2450-1
-
Martins, F.S., Elian, S.D.A., Vieira, A.T., Tiago, F.C.P., Martins, A.K.S., Silva, F.C.P., Souza, É.L.S., Sousa, L.P., Araújo, H.R.C., Pimenta, P.F., Bonjardim, C.A., Arantes, R.M.E., Teixeira, M.M. and Nicoli, J.R., 2011. Oral treatment with Saccharomyces cerevisiae strain UFMG 905 modulates immune responses and interferes with signal pathways involved in the activation of inflammation in a murine model of typhoid fever. International Journal of Medical Microbiology 301: 359-364. https://doi.org/10.1016/j.ijmm.2010.11.002
-
Martins, F.S., Silva, A.A., Vieira, A.T., Barbosa, F.H.F., Arantes, R.M.E., Teixeira, M.M. and Nicoli, J.R., 2009. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Archives of Microbiology 191: 623-630. https://doi.org/10.1007/s00203-009-0491-x
-
Maynard, C.L., Elson, C.O., Hatton, R.D. and Weaver, C.T., 2012. Reciprocal interactions of the intestinal microbiota and immune system. Nature 489: 231-241. https://doi.org/10.1038/nature11551
-
Melgar, S., Karlsson, A. and Michaëlsson, E., 2005. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. American Journal of Physiology – Gastrointestinal and Liver Physiology 288: G1328-G1338. https://doi.org/10.1152/ajpgi.00467.2004
-
Mendes, E., Acetturi, B.G., Thomas, A.M., Martins, F.d.S., Crisma, A.R., Murata, G., Braga, T.T., Camâra, N.O.S., Franco, A.L.d.S., Setubal, J.C., Ribeiro, W.R., Valduga, C.J., Curi, R., Dias-Neto, E., Tavares-de-Lima, W. and Ferreira, C.M., 2017. Prophylactic supplementation of Bifidobacterium longum 51A protects mice from ovariectomy-induced exacerbated allergic airway inflammation and airway hyperresponsiveness. Frontiers in Microbiology 8: 1732. https://doi.org/10.3389/fmicb.2017.01732
-
Mennigen, R., Nolte, K., Rijcken, E., Utech, M., Loeffler, B., Senninger, N. and Bruewer, M., 2009. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. American Journal of Physiology – Gastrointestinal and Liver Physiology 296: G1140-G1149. https://doi.org/10.1152/ajpgi.90534.2008
-
Neurath, M.F., 2014. Cytokines in inflammatory bowel disease. Nature Reviews Immunology 14: 329. https://doi.org/10.1038/nri3661
-
Ordás, I., Eckmann, L., Talamini, M., Baumgart, D.C. and Sandborn, W.J., 2012. Ulcerative colitis. The Lancet 380: 1606-1619. https://doi.org/10.1016/S0140-6736(12)60150-0
-
Perše, M. and Cerar, A., 2012. Dextran sodium sulphate colitis mouse model: traps and tricks. Journal of Biomedicine and Biotechnology 2012: 1-13. https://doi.org/10.1155/2012/718617
-
Philippe, D., Heupel, E., Blum-Sperisen, S. and Riedel, C.U., 2011. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. International Journal of Food Microbiology 149: 45-49. https://doi.org/10.1016/j.ijfoodmicro.2010.12.020
-
Ponder, A. and Long, M. D., 2013. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clinical Epidemiology 5: 237-247. https://doi.org/10.2147/CLEP.S33961
-
Ruiz, L., Delgado, S., Ruas-Madiedo, P., Sánchez, B. and Margolles, A., 2017. Bifidobacteria and Their Molecular Communication with the Immune System. Frontiers in Microbiology 8: 2345. https://doi.org/10.3389/fmicb.2017.02345
-
Rupa, P. and Mine, Y., 2012. Recent advances in the role of probiotics in human inflammation and gut health. Journal of Agricultural and Food Chemistry 60: 8249-8256. https://doi.org/10.1021/jf301903t
-
Serhan, C.N., Brain, S.D., Buckley, C.D., Gilroy, D.W., Haslett, C., O’Neill, L.A.J., Perretti, M., Rossi, A.G. and Wallace, J.L., 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB Journal 21: 325-332. https://doi.org/10.1096/fj.06-7227rev
-
Souza, T.C., Silva, A.M., Drews, J.R.P., Gomes, D.A., Vinderola, C.G. and Nicoli, J.R., 2013. In vitro evaluation of Bifidobacterium strains of human origin for potential use in probiotic functional foods. Beneficial Microbes 4: 179-186. https://doi.org/10.3920/BM2012.0052
-
Souza, T.C., Zacarías, M.F., Silva, A.M., Binetti, A., Reinheimer, J., Nicoli, J.R. and Vinderola, G., 2012. Cell viability and immunostimulating and protective capacities of Bifidobacterium longum 51A are differentially affected by technological variables in fermented milks. Journal of Applied Microbiology 112: 1184-1192. https://doi.org/10.1111/j.1365-2672.2012.05280.x
-
Vieira, A., Teixeira, M. and Martins, F., 2013. The role of probiotics and prebiotics in inducing gut immunity. Frontiers in Immunology 4: 445. https://doi.org/10.3389/fimmu.2013.00445
-
Vieira, A.T., Fagundes, C.T., Alessandri, A.L., Castor, M.G.M., Guabiraba, R., Borges, V.O., Silveira, K.D., Vieira, E.L.M., Gonçalves, J.L., Silva, T.A., Deruaz, M., Proudfoot, A.E.I., Sousa, L.P. and Teixeira, M.M., 2009. Treatment with a novel chemokine-binding protein or eosinophil lineage-ablation protects mice from experimental colitis. American Journal of Pathology 175: 2382-2391. https://doi.org/10.2353/ajpath.2009.090093
-
Vieira, A.T., Galvão, I., Amaral, F.A., Teixeira, M.M., Nicoli, J.R. and Martins, F.S., 2015. Oral treatment with Bifidobacterium longum 51A reduced inflammation in a murine experimental model of gout. Beneficial Microbes 6: 799-806. https://doi.org/10.3920/BM2015.0015
-
Vieira, A.T., Rocha, V.M., Tavares, L., Garcia, C.C., Teixeira, M.M., Oliveira, S.C., Cassali, G.D., Gamba, C., Martins, F.S. and Nicoli, J.R., 2016. Control of Klebsiella pneumoniae pulmonary infection and immunomodulation by oral treatment with the commensal probiotic Bifidobacterium longum 51A. Microbes and Infection 18: 180-189. https://doi.org/10.1016/j.micinf.2015.10.008
-
Wang, K.-Y., Li, S.-N., Liu, C.-S., Perng, D.-S., Su, Y.-C., Wu, D.-C., Jan, C.-M., Lai, C.-H., Wang, T.-N. and Wang, W.-M., 2004. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. American Journal of Clinical Nutrition 80: 737-741. https://doi.org/10.1093/ajcn/80.3.737
-
Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F., 2007. Chemically induced mouse models of intestinal inflammation. Nature Protocols 2: 541-546. https://doi.org/10.1038/nprot.2007.41
-
Yan, Y., Kolachala, V., Dalmasso, G., Nguyen, H., Laroui, H., Sitaraman, S.V. and Merlin, D., 2009. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE 4: e6073. https://doi.org/10.1371/journal.pone.0006073
-
Zakostelska, Z., Kverka, M., Klimesova, K., Rossmann, P., Mrazek, J., Kopecny, J., Hornova, M., Srutkova, D., Hudcovic, T., Ridl, J. and Tlaskalova-Hogenova, H., 2011. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS ONE 6: e27961. https://doi.org/10.1371/journal.pone.0027961
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 728 | 293 | 26 |
| Gesamttextansichten | 51 | 24 | 2 |
| PDF-Downloads | 31 | 11 | 6 |
Treatment with Bifidobacterium longum 51A attenuates intestinal damage and inflammatory response in experimental colitis
in Beneficial MicrobesSearch for other papers by F.A. Abrantes in
Current site
Google Scholar
PubMed
Search for other papers by B.B. Nascimento in
Current site
Google Scholar
PubMed
Search for other papers by M.E.R. Andrade in
Current site
Google Scholar
PubMed
Search for other papers by P.A.V. de Barros in
Current site
Google Scholar
PubMed
Search for other papers by C.T. Cartelle in
Current site
Google Scholar
PubMed
Search for other papers by F.S. Martins in
Current site
Google Scholar
PubMed
Search for other papers by J.R. Nicoli in
Current site
Google Scholar
PubMed
Search for other papers by R.M.E. Arantes in
Current site
Google Scholar
PubMed
Search for other papers by S.V. Generoso in
Current site
Google Scholar
PubMed
Search for other papers by S.O.A. Fernandes in
Current site
Google Scholar
PubMed
Search for other papers by V.N. Cardoso in
Current site
Google Scholar
PubMed
This study evaluated the effects of Bifidobacterium longum 51A on the intestinal mucosa and inflammatory response in experimental colitis. Colitis was induced by administration of 3.5% dextran sodium sulphate (DSS) solution for 7 days. Two periods of administration were performed: treatment (T) group, mice received Bifidobacterium only during disease induction (7 days); total treatment (TT) group, mice received Bifidobacterium for 10 days before and during disease induction. The probiotic effects on intestinal permeability, inflammatory infiltrate, histological analysis, cytokines, chemokines and sIgA were evaluated. Bifidobacterium administration in the T group showed reduction in intestinal permeability and lower IL-1β, myeloperoxidase, and eosinophil peroxidase levels compared to those in the colitis group (P<0.05). Bifidobacterium administration in the TT group attenuated severe lesions in the colon and reduced eosinophil peroxidase level (P<0.05). B. longum 51A treatment modality was more effective than total treatment and reduced the inflammatory response and its consequences on intestinal epithelium.
| Insgesamt | Letzte 365 Tage | In den letzten 30 Tagen | |
|---|---|---|---|
| Aufrufe von Kurzbeschreibungen | 728 | 293 | 26 |
| Gesamttextansichten | 51 | 24 | 2 |
| PDF-Downloads | 31 | 11 | 6 |
